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BACKGROUND: Predict (www.predict.nhs.uk) is an online, breast cancer prognostication and treatment benefit tool. The aim of this
study was to incorporate the prognostic effect of HER2 status in a new version (Predictþ ), and to compare its performance with the
original Predict and Adjuvant!.
METHODS: The prognostic effect of HER2 status was based on an analysis of data from 10 179 breast cancer patients from 14 studies in
the Breast Cancer Association Consortium. The hazard ratio estimates were incorporated into Predict. The validation study was
based on 1653 patients with early-stage invasive breast cancer identified from the British Columbia Breast Cancer Outcomes Unit.
Predicted overall survival (OS) and breast cancer-specific survival (BCSS) for Predictþ , Predict and Adjuvant! were compared with
observed outcomes.
RESULTS: All three models performed well for both OS and BCSS. Both Predict models provided better BCSS estimates than
Adjuvant!. In the subset of patients with HER2-positive tumours, Predictþ performed substantially better than the other two models
for both OS and BCSS.
CONCLUSION: Predictþ is the first clinical breast cancer prognostication tool that includes tumour HER2 status. Use of the model
might lead to more accurate absolute treatment benefit predictions for individual patients.
British Journal of Cancer (2012) 107, 800–807. doi:10.1038/bjc.2012.338 www.bjcancer.com
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Accurate prognostication is essential when selecting the most
appropriate adjuvant therapy following surgery for early breast
cancer. A number of predictive models are now available to help
estimate the survival for individual patients, including the
Nottingham Prognostic Index (NPI), Adjuvant and Predict, and
to date, these have all been based on known pathological
prognostic factors including tumour size, tumour grade and
lymph node status. The NPI, first described in1982 (Haybittle et al,
1982), has been prospectively validated (Todd et al, 1987;
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D’Eredita et al, 2001) and more recently updated (Blamey et al,
2007a) to provide accurate survival estimates following breast
cancer surgery, including individual survival estimates (Blamey
et al, 2007b). The introduction of Adjuvant!, a web-based
(www.adjuvantonline.com) prognostication tool, in 2001 (Ravdin
et al, 2001) went a step further by also providing absolute
treatment benefits for hormone therapy and chemotherapy by
applying risk reductions from the Early Breast Cancer Trialists
Collaborative Group (1998a, b) to breast cancer-specific mortality
estimates based on the Surveillance Epidemiology and End Results
Program (www.seer.cancer.gov). This model has been validated in
case cohorts from British Columbia (Olivotto et al, 2005), the
Netherlands (Mook et al, 2009) and the United Kingdom
(Campbell et al, 2009).
Prognostication is becoming more sophisticated, and additional
prognostic and predictive factors need to be considered in any
current prognostic and treatment benefit model. There is a
growing body of evidence to show that screen detection confers
an additional survival benefit beyond stage shift and also reduces
the risk of systemic recurrence when compared with symptomatic
cancers of a similar stage (Joensuu et al, 2004; Shen et al, 2005).
Recent studies have shown that the majority of the survival
advantage associated with breast screening can be explained by
this shift to an earlier stage at diagnosis, and more favourable
prognostic factors (Dawson et al, 2009), but approximately 25% of
the survival advantage is still unexplained (Wishart et al, 2008).
These findings were recently confirmed in a data set from the
Netherlands in which screen detection was associated with a 26
and 38% reduction in all-cause and breast cancer-specific
mortality, respectively (Mook et al, 2011). The authors from this
paper concluded that method of detection should be taken into
account when estimating individual prognosis.
Predict is an online prognostication and treatment benefit tool
developed in the United Kingdom, which is based on 5694 women
diagnosed in East Anglia from 1999 to 2003 (Wishart et al, 2010).
The model includes mode of detection and provides 5- and 10-year
survival estimates as well as treatment benefit predictions at both
time points, and it has been validated in an independent case
cohort from the United Kingdom and more recently in a British
Columbia data set wherein it was also compared with Adjuvant!
(Wishart et al, 2011). This comparison showed that Predict and
Adjuvant! provide accurate overall and breast cancer-specific
survival (BCSS) estimates that were comparable. However, the
Predict estimates did not utilise the mode of detection component
of the model as the mode of detection was not available for the
British Columbia cohort. Moreover, Adjuvant! does not take
account of the mode of detection. Predict was slightly better
calibrated for breast cancer-specific mortality with predicted
deaths being within 3.4% of observed deaths compared with
6.7% for Adjuvant!. Both models showed good discrimination
with similar area under the receiver-operator characteristic curve
(AUC; 0.723 vs 0.727 for Predict and Adjuvant, respectively).
Predict is now available online at www.predict.nhs.uk.
The aim of this study was to incorporate the prognostic effect of
HER2 status into Predict (hereafter referred to as Predictþ ), and
to compare the 10-year survival estimates from Predictþ with
Predict, Adjuvant! and the observed 10-year outcome from the
British Columbia data set.
METHODS
Prognostic effect of tumour HER2 status
Estimates for the prognostic effect of HER2 status were based on
an analysis of data from the Breast Cancer Association Consortium
(BCAC). Pathology data from 12 of these studies has been
previously published (Blows et al, 2010) and the analysis was
updated to include data from another 3 studies excluded from
the previous publication because of missing data on basal markers
that is not relevant for this analysis (Table 1). However, as the
validation cohort for this study overlaps substantially with the
British Columbia Cancer Agency (BCCA) case series published in
Blows et al (2010), this case series was excluded from the BCAC
data re-analysis. In addition, all patients diagnosed since 2004 were
excluded, to exclude patients likely to have been treated with
trastuzumab. In total, HER2 data were available for 10 179 cases
(7278 ER-positive and 2931 ER-negative, Table 2) for whom data
were also available for age at diagnosis, tumour size (p2, 2–4.9
and 5þ cm), tumour grade and nodal status. We estimated the
hazard ratio for HER2-positive disease compared with HER2-
negative disease using a Cox proportional hazards model stratified
by study and adjusted for size, grade and nodal status. Separate
regression models were used for ER-positive and ER-negative
cases. As we have shown previously (Blows et al, 2010), the hazard
ratio for HER2-positive disease decreases over time in women with
ER-positive breast cancer, so the log hazard ratio was modelled
to vary linearly with time. The effect of HER2 in women with
ER-negative breast cancer is not time-dependent.
The hazard ratios estimated from the BCAC data set were then
used to modify Predict, which is also based on a Cox proportional
hazards models. However, Predict was developed using a case
cohort of breast cancer cases of unknown HER2 status, and so the
underlying baseline hazard is representative of cases of average
HER2 status. The HER2 hazard ratio estimates based on the BCAC
data are for HER2-positive cases compared with HER2-negative
cases, and so these were rescaled to give an average hazard ratio of
unity using an estimated prevalence of HER2 of 9% in ER-positive
cases and 25% in ER-negative cases. The applied hazard ratios for
ER-positive cases are shown in Table 3. A fixed hazard ratio of 0.93
for HER2–negative cases and 1.27 for HER2–positive cases
compared with HER2 unknown cases was applied to the baseline
hazard of the ER-negative model.
Validation study population
We used the same case cohort from British Columbia, Canada,
which we used to validate the original version of Predict. The data
set has previously been described (Olivotto et al, 2005), but, in
brief, includes data from 1653 patients with information on HER2
status out of a total of 3140 patients with stage I or II invasive
breast cancer diagnosed in British Columbia, Canada, from 1989 to
1993, who were identified from the Breast Cancer Outcomes Unit
(BCOU) of the BCCA. The BCOU prospectively records demo-
graphical information, pathological information, staging, initial
treatment and outcome information including first loco-regional
and distant relapse, as well as date and cause of death. Outcome
data were reported annually by the treating oncologist, family
physician or by monthly death certificate flagging through
the British Columbia Cancer Registry and Department of Vital
Statistics for British Columbia.
Information obtained from the BCOU database included age at
diagnosis, sex, menopausal status, year of diagnosis, histology
(ductal, lobular, other), histological grade, tumour size, number of
lymph nodes sampled and number of lymph nodes positive,
lymphovascular invasion status, ER status, HER2 status, type of
local therapy (wide local excision, mastectomy, radiotherapy) and
type of adjuvant systemic therapy (none, chemotherapy, endocrine
therapy, both). The HER2 status was evaluated using TMAs as
previously described (Chia et al, 2008). Chemotherapy regimens
were categorised as four cycles of doxorubicin plus cyclopho-
sphamide; 6 months of cyclophosphamide, methotrexate and
fluorouracil, or other chemotherapy during this time period. None
of these patients received trastuzumab.
Study endpoints were overall survival (OS) and BCSS. Of 1653
cases used in this analysis, cause of death was unknown in 5,
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Table 1 Description of participating studies
Study Country
Case
ascertainment Case definition
Age range
(years) References
Amsterdam Breast
Cancer Study
The Netherlands Hospital-based All cases of operable, invasive cancer diagnosed from 1974–1994
in four Dutch hospitals. Familial non-BRCA1/2 cases o50 from
the Clinical Genetic Centre at the Netherlands Cancer Institute
23–50 Schmidt et al (2007)
Bavarian Breast Cancer
Case–Control Study
Germany Hospital-based
cases
Consecutive, unselected cases with invasive breast cancer
recruited at the University Breast Centre, Franconia in Northern
Bavaria during 2002–2006
27–86 Fasching et al (2008)
Helsinki Breast Cancer
Study
Finland Hospital-based (1) Consecutive cases (883) from the Department of Oncology,
Helsinki University Central Hospital 1997–1998 and 2000, (2)
consecutive cases (986) from the Department of Surgery, Helsinki
University Central Hospital 2001–2004, (3) familial breast cancer
patients (536) from the Departments of Oncology and Clinical
Genetics, Helsinki University Central Hospital(1995)
22–96 Syrjakoski et al (2000);
Kilpivaara et al (2005);
Fagerholm et al (2008)
Jewish General Hospital Canada Hospital-based Ashkenazi Jewish women diagnosed with non-metastatic, invasive
breast cancer at Jewish General Hospital, Montreal, between
1980 and 1995
26–66 Tischkowitz et al (2007)
Kuopio Breast Cancer
Study
Finland Women seen at Kuopio University Hospital between 1990 and
1995 because of breast lump, mammographic abnormality, or
other breast symptom, who were found to have breast cancer
23–92 Hartikainen et al (2005)
Mayo Clinic Breast
Cancer Study
USA Hospital-based Incident cases residing in six states (MN, WI, IA, IL, ND, SD) seen
at the Mayo Clinic in Rochester, MN, from 2002–2005
22–89 Olson et al (2007)
Melbourne
Collaborative Cohort
Study
Australia Cohort Incident cases diagnosed within the Melbourne Collaborative
Cohort Study during the follow-up from baseline (1990–1994) to
2004 of the 2 4469 participating women
30–82 Giles and English (2002)
Nottingham Breast
Cancer Case Series
UK Hospital-based Primary operable breast carcinoma patients presenting from 1986
to 1998, and entered into the Nottingham Tenovus Primary
Breast Carcinoma Series
26–93 Rakha et al (2007)
Oulu Breast Cancer
Study
Finland Hospital-based Consecutive incident cases diagnosed at the Oulu University
Hospital, 2000–2004
28–92 Erkko et al (2007)
NCI Polish Breast
Cancer Study
Poland Population-based Incident cases from 2000–2003 identified through a rapid
identification system in participating hospitals covering B90% of
all eligible cases; periodic check against the cancer registries in
Warsaw and Ło´dz´ to assure complete identification of cases
27–75 Garcia-Closas et al
(2006)
Sheffield Breast Cancer
Study
UK Hospital-based Women with pathologically confirmed breast cancer, recruited
from surgical outpatient clinics at the Royal Hallamshire Hospital,
Sheffield, 1998–2002; cases are a mixture of prevalent and
incident disease
29–93 Rafii et al (2002);
MacPherson et al (2004)
Study of Epidemiology
and Risk factors in
Cancer Heredity
UK Population-based Two groups of cases identified through East Anglian Cancer
Registry: (1) prevalent cases diagnosed age o55 years from
1991–1996 and alive when study started in 1996; (2) incident
cases diagnosed age o70 years diagnosed after 1996
23–69 Callagy et al (2006)
University of British
Columbia Breast Cancer
Trials
Canada Hospital-based Women with stage I to III breast cancer, who participated in four
different British Columbia Cancer Agency clinical trials between
1970 and 1990, and all received chemotherapy
22–90 Ragaz et al (1997);
Ragaz et al (2005)
Vancouver General
Hospital
Canada Hospital-based Women with primary breast cancer, who underwent surgery at
Vancouver General Hospital 1975–1995
28–91 Tischkowitz et al (2007)
Table 2 Number of cases by study, ER status and HER2 status
ER-positive ER-negative
Study HER2 (%) HER2þ (%) Total HER2 (%) HER2þ (%) Total
ABCS 512 (87) 74 (13) 586 231 (77) 69 (23) 300
BBCC 585 (88) 77 (12) 662 164 (73) 62 (27) 226
HEBCS 173 (88) 23 (12) 196 37 (77) 11 (23) 48
JGH 166 (94) 11 (6) 177 77 (79) 21 (21) 98
KBCS 281 (93) 20 (7) 301 59 (67) 29 (33) 88
MCBCS 386 (84) 71 (16) 457 67 (77) 20 (23) 87
MCCS 307 (93) 24 (7) 331 99 (76) 31 (24) 130
NOBCS 1006 (96) 40 (4) 1046 346 (82) 76 (18) 422
OBCS 390 (91) 39 (9) 429 72 (68) 34 (32) 106
PBCS 656 (95) 34 (5) 690 289 (80) 71 (20) 360
SBCS 201 (93) 15 (7) 216 70 (84) 13 (16) 83
SEARCH 1447 (91) 135 (9) 1582 334 (75) 113 (25) 447
UBC 299 (76) 93 (24) 392 296 (66) 152 (34) 448
VGH 201 (94) 12 (6) 213 42 (72) 16 (28) 58
Total 6610 (91) 668 (9) 7278 2183 (75) 718 (25) 2901
Abbreviations: ABCS¼Amsterdam Breast Cancer Study; BBCC¼ Bavarian Breast Cancer Case–Control Study; ER¼ oestrogen receptor; HEBCS¼Helsinki Breast Cancer
Study; HER2¼ human epidermal growth factor receptor-2; JGH¼ Jewish General Hospital; KBCS¼ Kuopio Breast Cancer Study; MCBCS¼Mayo Clinic Breast Cancer Study;
MCCS¼Melbourne Collaborative Cohort Study; NOBCS¼Nottingham Breast Cancer Case Series; OBCS¼Oulu Breast Cancer Study; PBCS¼NCI Polish Breast Cancer
Study; SBCS¼ Sheffield Breast Cancer Study; SEARCH¼ Study of Epidemiology and Risk factors in Cancer Heredity; UBCBCT¼University of British Columbia Breast Cancer
Trials; VGH¼Vancouver General Hospital.
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and so 1648 cases were used for the analysis of BCSS.
Ten-year-predicted OS and BCSS were calculated for each patient
using Predictþ , Predict and Adjuvant! (standard version 8) by
investigators blinded to the actual outcome data for each patient
after entry of patient age, tumour size, number of positive nodes,
tumour grade, ER status, HER2 status (Predictþ only) and
adjuvant systemic therapy. The default comorbidity setting of
‘minor symptoms’ and the chemotherapy option chosen was
‘anthracycline-containing; X4 cycles’ were used in Adjuvant!. The
‘second-generation’ chemotherapy option (anthracycline-contain-
ing regimens) was used in Predictþ and Predict. The mode of
detection input was not used in Predict or Predictþ , as this
information was not available in the British Columbia data set.
Ten-year-predicted OS and BCSS from Predictþ , Predict and
Adjuvant were compared with observed 10-year OS and BCSS.
Model calibration is a comparison of the predicted mortality
estimates from each model with the observed mortality. In addition
to comparing calibration in the complete data set, we evaluated
calibration within strata of other prognostic variables. We also
evaluated calibration within quartiles of predicted mortality.
A goodness-of-fit test was carried out by using a w2-test based on
the observed and predicted number of events (4 d.f.). Model
discrimination was evaluated by calculating the AUC calculated for
10-year breast cancer-specific and overall mortality. This is a
measure of how well the models identify those patients with worse
survival. The AUC is the probability that the predicted mortality
from a randomly selected patient who died will be higher than the
predicted mortality from a randomly selected survivor.
RESULTS
The calibration of Predict for both all-cause mortality and for
breast cancer-specific mortality was improved by the incorpora-
tion of HER2 status. Adjuvant! performed slightly better than
Predict and Predictþ for all-cause mortality, but both Predict and
Predictþ outperformed Adjuvant! for breast cancer-specific
mortality. All three models slightly underestimated the observed
number of deaths. The total number of deaths predicted by
Adjuvant was within 6.1% of that observed (492 vs 524, P¼ 0.16)
compared with 8.8% for Predict (478 vs 524, P¼ 0.04) and 8.4% for
Predictþ (480 vs 524, P¼ 0.05). The total number of breast
cancer-specific deaths predicted by Adjuvant was within 14% of
that observed (311 vs 360, P¼ 0.01) compared with 3.6% for
Predict (347 vs 360, P¼ 0.49) and 2.5% for Predictþ (351 vs 360,
P¼ 0.60). Table 4 shows the observed and predicted all-cause
10-year OS by various clinico-pathological sub-groups. All models
performed well in most subgroups. Notable exceptions were the
performance in women aged 20–35 years, in which all three models
underpredicted the actual number of deaths by 32%, and in HER2-
positive cases, in which Adjuvant and Predict underestimated the
number of deaths by close to 20% compared with just 9% for
Predictþ . None of these differences were statistically significant
Table 3 Hazard ratio by HER2 status by time since diagnosis in
ER-positive breast cancer
HER2 status
Year after diagnosis Unknown Positive Negative
1 1 1.84 0.95
2 1 1.70 0.95
3 1 1.58 0.96
4 1 1.47 0.97
5 1 1.36 0.97
6 1 1.26 0.98
7 1 1.17 0.99
8 1 1.08 0.99
9 1 1.01 1.00
10 1 0.93 1.01
Abbreviations: ER¼ oestrogen receptor; HER2¼ human epidermal growth factor
receptor-2. Weighted average hazard ratio for HER2þ and HER2 ¼ 1.
Table 4 Observed and predicted 10-year all-cause mortality by
demographical, pathological and treatment characteristics
Deaths
Number Observed Adjuvant Predict Predictþ
Age group (years)
20–35 55 22 15 15 15
36–50 492 120 112 119 119
51–65 523 152 133 132 133
66–75 433 153 153 141 142
76þ 150 76 79 71 71
Menopausal status
Pre- 520 135 121 128 128
Post 1089 380 360 339 341
Peri-/unknown 44 8 10 11 11
Morphology
Ductal 1489 479 440 428 432
Lobular 132 38 43 40 40
Other 32 5 8 8 8
Grade
1 104 22 19 15 15
2 778 208 203 176 177
3 694 269 247 265 268
Unknown 77 24 23 20 20
LV invasion
Negative 868 233 230 218 218
Positive 715 262 239 238 241
Unknown 70 26 22 20 20
Node status
Negative 976 235 230 215 216
Positive 677 288 262 262 265
Tumour size
1–10 210 40 39 40 40
11–20 745 196 189 186 187
21–50 698 287 264 251 253
ER status
ER 350 123 124 129 130
ERþ 1303 400 367 348 350
Local Rx
BCSþRT 814 200 205 200 200
MastþRT 169 77 74 77 78
Mast 670 246 213 201 202
Systemic Rx
None 660 175 170 161 162
Hormone 526 201 188 175 176
Chemo 317 96 93 97 98
Both 150 51 41 43 44
HER2
Negative 1450 434 420 405 398
Positive 203 90 72 73 82
Total 1653 524 492 478 480
Abbreviations: BCS¼ breast conserving surgery; ER¼ oestrogen receptor; HER2¼
human epidermal growth factor receptor-2; LV¼ lymphovascular; RT¼ radiotherapy.
The sum of the predicted events within categories may differ from the sum of the
observed events because of rounding errors in the predicted events.
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(P40.05). We also compared the predicted mortality with that
observed for women in each quartile of predicted risk. Calibration
was good for Adjuvant! across all risk categories (goodness-of-fit,
P¼ 0.51), and reasonable for Predictþ (goodness-of-fit, P¼ 0.042)
and Predict (goodness-of-fit, P¼ 0.032) (Figures 1A–C). Table 5
shows the observed 10-year breast cancer-specific mortality
compared with that predicted by Predictþ , Predict and Adjuvant.
Again, each model performed well across most subgroups, except
in women aged 20–35 years wherein they all underpredicted the
actual number of deaths by 32% (P40.05). In HER2-positive
patients, the total number of breast cancer-specific deaths
predicted by Predictþ was within 5% of observed (71 vs 75,
P¼ 0.64) compared with 20% for Predict (n¼ 60 vs 75, P¼ 0.08)
and 29% for Adjuvant (53 vs 75, P¼ 0.01). Calibration across the
quartiles of predicted breast cancer risk was good for Predictþ
(goodness-of-fit, P¼ 0.11) and Predict (goodness-of-fit, P¼ 0.068),
and reasonable for Adjuvant! (goodness-of-fit, P¼ 0.001) (Figures
1D–F). Model discrimination was similar for all three models
with AUCs for breast cancer-specific mortality of 0.665, 0.661 and
0.649 for Predictþ , Predict and Adjuvant!, respectively.
DISCUSSION
Predict was developed using a flexible, Cox proportional hazards
model that enables the easy incorporation of additional prognostic
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Figure 1 Calibration plots of observed outcomes with 95% confidence intervals against predicted outcomes by quartiles of the predicted value. Overall
survival predicted by (A) Predictþ (B) Predict and (C) Adjuvant!, and breast cancer-specific survival predicted by (D) Predictþ (E) Predict and
(F) Adjuvant!.
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factors using external estimates of the prognostic effect of such a
factor. We have used this flexibility to incorporate the prognostic
effect of HER2 derived from a large multi-centre study. A key
feature of Predict, and one that differentiates it from Adjuvant!,
is that it uses different underlying models for ER-positive and
ER-negative disease. This is particularly important as the effect of
other prognostic variables is often different according to ER status.
This difference is particularly marked for HER2 status, where the
effect of HER2 is strongly time-dependent in ER-positive cases but
not for ER-negative cases. Our results confirm that the inclusion of
HER2 status in the clinical prognostication tool Predict improves
both model discrimination and calibration. The improvement in
model fit was most pronounced in the HER2-positive subset of
patients and was particularly marked for breast cancer-specific
mortality. Given that it is breast cancer-specific mortality that is
reduced by adjuvant therapy (Early Breast Cancer Trialists
Collaborative Group, 1998a, b), it is likely that improved model
performance will lead to more accurate predictions of the absolute
benefit of treatment. Adjuvant! performed better than either
Predict or Predictþ for overall mortality. This might be expected
as the background mortality data on which Adjuvant! is based are
from North America, whereas Predict is based on background
mortality data from the United Kingdom.
The weaknesses of our study also need to be considered in
interpreting our results. There were some missing data for the
BCAC cohorts used to derive the HER2-specific hazard ratios and
for the BCOU cohort. Data were missing for multiple reasons, but
the major reason was because of unavailability of archival
pathology material. Although it is possible that there is some
selection bias in the missing data – for example, pathology
material is more likely to be unavailable for small tumours – any
bias is unlikely to be large. This notion is supported by the results
of the validation in the independent data from the BCOU cohort.
As we have described previously, none of the models performed
very well in the youngest age group. The reasons for this are
unclear, but probably reflect the fact that the data on which the
models were based included relatively small numbers of patients in
this age group.
The online version of Predict includes survival estimates and
treatment benefit at 5 and 10 years post diagnosis. Four clinical
trials have now reported on the benefit of trastuzumab therapy –
FinHER (Joensuu et al, 2009), HERA (Smith et al, 2007),
B31/N9831 (Romond et al, 2005; Perez et al, 2010) and BCIRG006
(Slamon et al, 2011). The relative reduction in the all-cause
mortality has ranged from 0.33 to 0.45. Two studies reported
results stratified by tumour hormone-receptor status neither of
which found evidence for heterogeneity (Romond et al, 2005;
Smith et al, 2007; Perez et al, 2010). The new version of Predictþ ,
including trastuzumab benefit at 5 years is available at
www.predict.nhs.uk.
One of the key advantages of the Predict models is that they
include mode of detection as one of the input parameters.
As previously discussed, screen detection appears to confer an
additional survival advantage over and above known prognostic
factors. Unfortunately, as screening data was not available in the
British Columbia data set, it was not possible to use this feature
when running the Predict models, so the default setting was
‘unknown’ for all patients. Thus, we cannot estimate the
performance of the Predict models if the mode of detection were
known. However, it is very likely that model performance would
improve with the addition of mode-of-detection data. In addition,
a recent publication has called for the mode of detection to be
taken into account when deciding optimal adjuvant therapy for an
individual patient (Mook et al, 2011). Predictþ can now provide
such a model with the added benefit of the inclusion of HER2
status as well as the absolute treatment benefit of trastuzumab at
5 years. Further validations of Predictþ in data sets where the
mode of detection, HER2 status and trastuzumab treatment are
recorded are planned in the near future.
This study reports the first successful inclusion of HER2 status
in a prognostic model (Predictþ ) based on known clinical and
pathological factors. The study has demonstrated a marked
Table 5 Observed and predicted 10-year breast cancer-specific mortality
by demographical, pathological and treatment characteristics
Deaths from breast cancer
Number Observed Adjuvant Predict Predictþ
Age group
20–35 55 22 15 15 15
36–50 492 118 102 110 110
51–65 522 102 96 106 108
66–75 430 88 76 86 87
76þ 149 30 23 31 31
Menopausal status
Pre 520 133 110 118 119
Peri-/Unknown 1085 221 192 220 222
Post 43 6 9 9 9
Morphology
Ductal 1485 340 281 314 318
Lobular 131 18 24 26 26
Other 32 2 7 7 7
Grade
1 104 4 5 5 5
2 775 133 108 104 104
3 693 206 183 225 228
Unknown 76 17 15 14 14
LV invasion
Negative 864 144 129 142 142
Positive 714 196 168 190 193
Unknown 70 18 13 14 14
Node status
Negative 972 132 117 128 129
Positive 676 228 194 219 221
Tumour size
1–10 210 22 14 21 21
11–20 741 118 101 121 122
21–50 697 220 196 205 208
ER status
ER 350 104 102 113 114
ERþ 1298 256 209 234 236
Local Rx
BCSþRT 810 140 128 142 142
MastþRT 169 59 59 69 70
Mast 669 161 124 137 139
Systemic Rx
None 658 100 88 99 99
Hormone 523 121 102 117 118
Chemo 317 94 86 92 93
Both 150 45 36 40 40
HER2
Negative 1445 285 258 287 280
Positive 203 75 53 60 71
Total 1648 360 311 347 351
Abbreviations: BCS¼ breast conserving surgery; ER¼ oestrogen receptor; HER2¼
human epidermal growth factor receptor-2; LV¼ lymphovascular; RT¼ radiotherapy.
The sum of the predicted events within categories may differ from the sum of the
observed events because of rounding errors in the predicted events.
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improvement in 10-year BCSS estimates using Predictþ compared
with the original Predict model for HER2-positive patients. Both
Predict models provide better BCSS estimates than Adjuvant! in
HER2-positive patients in this data set. This improvement in BCSS
prognostication for HER2-positive patients was not achieved at the
expense of the HER2-negative cohort, wherein both Predict and
Predictþ performed better than Adjuvant. Predictþ also
provided better breast cancer-specific mortality estimates that
Predict and Adjuvant. This is extremely important for optimal
model function, as it is the breast cancer-specific mortality that is
reduced by the relative risk reductions of adjuvant therapy, and
this improvement in model performance by Predictþ should lead
to more accurate absolute treatment benefit predictions for
individual patients.
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